Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from AbbVie

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.

MarketBeat

An Experimental Myeloma Drug Given Monthly Outperformed Standard Options in Patients Who Exhausted Three Treatment Classes

AbbVie reports that its investigational drug etentamig produced a 74% response rate in relapsed multiple myeloma, against 45.7% for standard therapies.

Medical Daily

How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks

AbbVie has underperformed the healthcare peers over the past year, and analysts remain very optimistic about the stock’s outlook.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Advocacy Group Says a Medicare Rule Change Delayed Price Negotiation for a Costly AbbVie Drug by Seven Years

Public Citizen says a CMS eligibility change kept AbbVie's Creon out of Medicare price negotiation for seven extra years. Here is how it works.

Medical Daily

What Are Wall Street Analysts' Target Price for AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Barchart

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

MarketBeat

AbbVie Earnings Preview: What to Expect

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Markets Have Been Anything But Calm. Jefferies Thinks These Low-Stress Stocks Can Still Deliver Returns.

Jefferies says a group of established companies with healthy cash flow and limited momentum could offer investors a steadier place to ride out a volatile market.

International Business Times

AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

Barchart

The FDA Just Approved a Powerful Biologic for Children as Young as 6 with Severe Psoriasis or Psoriatic Arthritis

FDA approved Skyrizi for children 6+ with moderate-severe psoriasis or psoriatic arthritis June 26, 2026. It's the first IL-23 inhibitor for kids under 40 kg. Here's what parents should know.

Medical Daily

AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.

Apogee’s rally may be over, but AbbVie’s upside from the deal could just be getting started.

Barchart

The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

Barchart

Wall Street ends mixed as investors focus on Iran talks

US stocks have closed mostly lower as investors assess progress in the ‌latest round of negotiations involving the United States and Iran.

AAP

US stocks today: S&P 500, Dow tick higher as investors weigh Mideast negotiations

Wall Street's major indexes opened little changed on Monday as investors returned from the long holiday weekend and awaited clarity on US-Iran negotiations,

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

MarketBeat

Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions. Speaking at a Jefferies fireside c

The Guardian - UK

Life-prolonging drug for advanced ovarian cancer gets go-ahead in England

Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 years

Evening Standard

'Significant breakthrough' as new ovarian cancer treatment approved for NHS use

A former NHS worker from north London who is taking the drug says the new treatment has let her ‘get on with my life’

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Breakthrough ovarian cancer drug that extends lives to be free on NHS for first time

Experts have hailed the ‘landmark’ decision from the National Institute for Health and Care Excellence to approve the treatment for NHS use

Barchart

AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

MarketBeat

5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade

Five high-yield names spanning pharmaceuticals, consumer staples, energy, and ETFs offer income investors compelling yields and durable businesses for a ten-year hold.

Barchart

AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.

Q1 earnings show this Dividend King still looks built for the long term.

MarketBeat

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

MarketBeat

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

AbbVie's early 2026 price pullback is an irresistable opportunity for buy-and-hold investors looking for income and compounding opportunities.

Barchart

Only 3 Dividend Kings Passed This Brutal Screen. They Could Pay You Well for Years to Come.

Three Dividend Kings with 50+ years of raises combine reliable income, solid growth, and analyst support, making them stand out in a shaky market.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.